About the Journal
Journal of Oncology Research and Therapy an esteemed open-access publication dedicated to ensure that crucial research reaches a global audience, fostering collaboration and innovation among researchers, clinicians, and healthcare professionals.
Scope:
Journal covers broad spectrum of topics in the field medical, surgical, and radiation oncology, along with clinical oncology.
Including but not limited to
Diagnostic Advances: Within the realm of diagnostic advances, "Journal of Oncology Research and Therapy" (JONT) delves into the multifaceted landscape of cancer diagnosis. We explore an array of methodologies, from the precision of biopsy and the insight of endoscopy to the intricate imaging techniques.
Therapeutic Innovations: In the realm of therapeutic innovations, JONT aims to publish the latest advancements in cancer treatment modalities. From traditional approaches such as surgery and chemotherapy to cutting-edge techniques like radiotherapy and immunotherapy, we delve into the diverse arsenal of treatments available. Moreover, we explore the transformative potential of personalized medicine, driven by genetic and molecular markers, in revolutionizing cancer care.
Palliative Care: In acknowledging the pivotal role of palliative care, Journal of Oncology Research & Therapy serves for disseminating studies focused on enhancing patient well-being and managing symptoms in advanced cancer. Recognizing the significance of quality of life, our publication is committed to spotlighting research that advances the understanding and delivery of palliative care in oncology.
Read More At Aims and Scope Page
Editorial Team:
Our esteemed editorial team comprises leading experts and researchers in the field of oncology. They bring a wealth of experience and a commitment to maintaining the highest standards of scientific integrity. The rigorous peer-review process ensures that published articles meet these standards and contribute meaningfully to the field.
Publication Frequency:
The Journal is published quarterly, with four issues released annually. This regular schedule ensures a steady flow of the latest research findings and developments in the field of oncology, allowing our readers to stay abreast of cutting-edge advancements throughout the year.
Abstracting and Indexing:
- Each publication is assigned with Digital Object Identifier (DOI) number – Crossref.
- Scilit
- ResearchGate
- Google Scholar
- ScienceGate
- Semantic Scholars
- ACADEMIA
- Dimensions AI
- FatCat Wiki
- Internet Archive Scholar
- Directory of Open Access Scholarly Resources
- CrossRef
- Genamics - JournalSeek
- Academic Keys
- ResearchBib - Academic Research Index
- Geneva Foundation for Medical Education and Research
- International Innovative Journal Impact Factor (IIJIF)
- Open J-Gate
- Directory of Journals indexing
- Scopus Impact Factor
- NIH funded articles in the field will be assigned for PubMed inclusion
Why Choose Journal
- High Quality Articles Published.
- High Impact Factor Journal.
- Indexing and Abstracting in Major Databases
- We maintain high standard peer review publications.
- We ensure optimum quality standard is maintained in every publication.
- Increased visibility of the publication and provides free, unrestricted global access.
- We provide higher readership, visibility and impact of your publications, we have dedicated marketing team to reach your work to broad audience.
- The authors reserve the copyrights of the article and articles are published under a Creative Commons Attribution License.
Submit Your Manuscript:
We invite researchers, clinicians, and scientists to submit their original contributions to the Journal of Oncology Research and Therapy. Our platform provides a unique opportunity to share your work with the global oncology community and contribute to the collective knowledge in the fight against cancer.
Editorial Board
Recently Published Articles
Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma
Patil R, Sun T, Chepurna O, Khoobchandani M, Rudensky S, Holler E, Ljubimova JY, Black KL
Comparison of Single Agent Check-Point Inhibitors as First-Line Treatment in NSCLC Patients with High PD-L1-Expression
Kraus FM, Traut A, Gubelt L, Nilius G, Volmerig J, Koziorowski A, Stöver I, Grabellus F, Stahl, M, Christoph DC
Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers
Ahmad A. Tarhini, Dale Hedges, Aik Choon Tan, Paulo Rodriguez , Vineeth Sukrithan, Aakrosh Ratan, Mar-tin D McCarter, John Carpten, Howard Colman,, Alexandra P Ikeguchi0, Igor Puzanov, Susanne M. Arnold, Michelle L. Churchman, Patrick Hwu, Jose R Con
Anticancer Effect of Osmanthus Heterophilus Leaf Extract Through Inhibition of mTOR Phosphorylation And Upregulation of Cytokeratin 18 in Head and Nec
Jeong DH,, Kim HW, Kim J, Oh DS, Cho E
Survival Analysis of Thymus Epithelial Tumors, Experience of an Oncological Center in Mexico
Nehmad-Misri C, Martínez Herrera JF, Gerson R
Challenges for Follow-Up of Sides Effects and Sequelae After Ovarian and Endometrial Cancers Treatments
Dubot Poitelon C, Gernier F, Joly F
CHK1 siRNA Containing Gemcitabine and Chemically Modified Nucleotides Shows Antitumoral Activity in Vitro and in Vivo
Halami B#, Kim W#, Ye Z, Neupane N, Bawazir N, Zhang G, Simonenko V, Lu P, Evans DM
Targeting of the Immune System - From Late-Stage Treatment to Upfront Neoadjuvant Therapy in Non-Small-Cell Lung Cancer
Daniel Rosas, Min Jee Kim, Matthew Salzberg, Spencer Streit, Andres M. Alvarez-Pinzon, Luis E. Raez
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) - Current State of knowledge
Adam Szostak, Joanna Jonska-Gmyrek